BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 24951323)

  • 1. Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy.
    Koie T; Ohyama C; Yamamoto H; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Kitayam M; Hirota K
    Urol Oncol; 2014 Aug; 32(6):820-5. PubMed ID: 24951323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
    Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
    Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of preoperative butyrylcholinesterase level as an independent predictor of survival in patients with upper urinary tract urothelial carcinoma treated with nephroureterectomy.
    Noro D; Koie T; Hashimoto Y; Tanaka T; Ohyama C; Tobisawa Y; Yoneyama T; Imai A; Hatakeyama S; Yamamoto H; Kitayama M; Hirota K
    Jpn J Clin Oncol; 2018 Feb; 48(2):184-189. PubMed ID: 29177431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
    Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
    Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
    Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
    Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy.
    Gondo T; Nakashima J; Ohno Y; Choichiro O; Horiguchi Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
    Urology; 2012 May; 79(5):1085-91. PubMed ID: 22446338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score.
    Gakis G; Todenhöfer T; Renninger M; Schilling D; Sievert KD; Schwentner C; Stenzl A
    BJU Int; 2011 Dec; 108(11):1800-5. PubMed ID: 21507193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
    Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y
    Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
    Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
    Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
    Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
    J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone.
    Cole CJ; Pollack A; Zagars GK; Dinney CP; Swanson DA; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 May; 32(2):331-40. PubMed ID: 7751174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of cystoscopy findings following neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Mansour AM; Soloway MS; Eldefrawy A; Singal R; Joshi S; Manoharan M
    Can J Urol; 2015 Apr; 22(2):7690-7. PubMed ID: 25891331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy.
    Moschini M; Sharma V; Dell'oglio P; Cucchiara V; Gandaglia G; Cantiello F; Zattoni F; Pellucchi F; Briganti A; Damiano R; Montorsi F; Salonia A; Colombo R
    BJU Int; 2016 Apr; 117(4):604-10. PubMed ID: 25851271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience.
    Yafi FA; Aprikian AG; Chin JL; Fradet Y; Izawa J; Estey E; Fairey A; Rendon R; Cagiannos I; Lacombe L; Lattouf JB; Bell D; Drachenberg D; Kassouf W
    BJU Int; 2011 Aug; 108(4):539-45. PubMed ID: 21166753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node-positive bladder cancer who are unfit for or who decline adjuvant chemotherapy.
    Zehnder P; Studer UE; Daneshmand S; Birkhäuser FD; Skinner EC; Roth B; Miranda G; Burkhard FC; Cai J; Skinner DG; Thalmann GN; Gill IS
    BJU Int; 2014 Apr; 113(4):554-60. PubMed ID: 24131453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients.
    Hautmann RE; de Petriconi RC; Pfeiffer C; Volkmer BG
    Eur Urol; 2012 May; 61(5):1039-47. PubMed ID: 22381169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis.
    Bruins HM; Aben KK; Arends TJ; van der Heijden AG; Witjes AJ
    Urol Oncol; 2016 Apr; 34(4):166.e1-6. PubMed ID: 26705102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis.
    Fajkovic H; Cha EK; Jeldres C; Robinson BD; Rink M; Xylinas E; Chromecki TF; Breinl E; Svatek RS; Donner G; Tagawa ST; Tilki D; Bastian PJ; Karakiewicz PI; Volkmer BG; Novara G; Joual A; Faison T; Sonpavde G; Daneshmand S; Lotan Y; Scherr DS; Shariat SF
    Eur Urol; 2013 Nov; 64(5):837-45. PubMed ID: 22877503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies.
    Zhang M; Tao R; Zhang C; Shen Z
    Urology; 2010 Oct; 76(4):902-7. PubMed ID: 20709377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.